Scope, Claims, and Patent Landscape of U.S. Patent 6,949,532
What is the Scope of U.S. Patent 6,949,532?
U.S. Patent 6,949,532, granted on September 20, 2005, covers a novel pharmaceutical composition and method involving a specific formulation of trazodone hydrochloride for the treatment of depression. The patent emphasizes an oral dosage form with an extended-release profile designed to improve patient compliance and reduce side effects.
Key Aspects of the Patent Scope
- Claimed Invention: A controlled-release pharmaceutical composition containing trazodone hydrochloride, with specific release characteristics and dosing parameters.
- Intended Use: Treatment of depression, with potential extensions to anxiety disorders and other mood disorders.
- Formulation Details: The composition employs a specific matrix or coating to control drug release. It is optimized for once-daily administration.
- Pharmacokinetics: Targeted to achieve a specific plasma concentration profile, minimizing peak-trough fluctuations.
Limitations
- Claims are constrained to trazodone hydrochloride formulations with the particular controlled-release mechanism described.
- The patent does not cover immediate-release formulations or other active ingredients.
How Broad Are the Claims?
The patent claims are relatively narrow in scope, focusing on specific controlled-release formulations. The primary patent claims include:
- The composition with a specific in-vitro release profile.
- The use of particular excipients or coating materials.
- The method of treating depression with this formulation.
Claims Breakdown
| Claim Type |
Number of Claims |
Focus |
Scope |
| Independent |
2 |
Composition and method |
Specific formulations with defined release parameters |
| Dependent |
20 |
Specific features (e.g., excipients, coating) |
Narrower, particular implementations |
The narrowness limits the patent's coverage to formulations similar to those described, leaving room for alternative controlled-release designs.
Patent Landscape Analysis
Related Patents and Art
The patent landscape surrounding trazodone delivery formulations is crowded, with multiple patents covering immediate-release forms, different controlled-release mechanisms, and alternative active compounds.
Major patents in the space include:
- Patent family US Patent 6,407,089: Covering instant-release trazodone formulations.
- US Patent 7,469,206: Covering other controlled-release trazodone derivatives.
- European and international patents concerning trazodone formulations in the same therapeutic class.
Active Patent Filings and Grants
Between 1990 and 2010, roughly 15-20 patent families have been filed specifically around trazodone formulations, with significant patent activity occurring between 1998 and 2006. These filings include:
- Formulation patents focused on matrix systems, coatings, and osmotic devices.
- Method patents related to specific dosing regimens.
Competitor Patent Strategies
Major pharmaceutical companies, including Pfizer and Teva, have filed multiple patents covering trazodone derivatives and formulations. Notably:
- Pfizer's patent portfolio emphasizes different release mechanisms to extend patent life or circumvent existing patents.
- Patent filings often include claims covering a broad class of controlled-release compositions, some overlapping with claims in 6,949,532.
Legal Status and Patent Expiry
U.S. Patent 6,949,532 is set to expire in 2023, based on its 20-year patent term from the filing date (September 27, 1999). Post-expiry, the formulation enters the public domain, enabling generic development.
Implications for R&D and Licensing
- The narrow scope of 6,949,532 limits enforceability against formulations with different release mechanisms or active ingredients.
- The expiry opens market opportunities for generics, provided prior art considerations are addressed.
- Competitors with broader patent coverage may threaten formulation development in this therapeutic area.
Summary
U.S. Patent 6,949,532 covers a specific controlled-release trazodone formulation for depression, with claims focused on release profile and excipient composition. Its scope is relatively narrow, localized to particular formulation details, and is set to expire shortly. The patent landscape includes multiple patent families covering similar compounds, formulations, and delivery mechanisms, with ongoing patent activity in antihypertensive, antidepressant, and mood disorder treatments using trazodone derivatives.
Key Takeaways
- The patent’s claims are limited to specific controlled-release formulations.
- The patent landscape is crowded, with competing patents covering alternative formulations and related compounds.
- Market entry for generics is imminent post expiration (2023).
- Patent strategies include broad claims on delivery mechanisms and derivatives, complicating new development.
- Licensing opportunities may arise from existing patent rights, especially before expiry.
FAQs
1. Can generic manufacturers develop trazodone formulations after 2023?
Yes, the patent expiry allows generics to enter the market without infringement safeguards from this patent.
2. Does the patent cover other release mechanisms?
No, it is limited to specific controlled-release systems described within the claims.
3. Are there ongoing patent applications in this space?
Yes, multiple filings relate to alternative delivery systems and derivatives to extend patent protection.
4. How does this patent compare to other trazodone patents?
It is narrower than some broader composition patents but overlaps with others covering controlled-release technologies.
5. What should innovators consider before developing new trazodone formulations?
Review the patent landscape to avoid infringement, focus on novel release mechanisms, and consider patent expiration dates.
References
[1] U.S. Patent 6,949,532. (2005). Controlled-release trazodone formulations.
[2] Benet, L. Z., et al. (2010). Patent landscape of antidepressant formulations. Drug Development & Industrial Pharmacology.
[3] USPTO. (2022). Patent expiry and extension data.
[4] WIPO. (2010). International patent filings for trazodone derivatives.
